These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24879985)

  • 1. DILI and drug development: a regulatory perspective.
    Avigan MI
    Semin Liver Dis; 2014 May; 34(2):215-26. PubMed ID: 24879985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
    Church RJ; Watkins PB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
    Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
    Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.
    Lewis JH
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2173-89.e8. PubMed ID: 26116527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and predictive performance and standardized threshold of traditional biomarkers for drug-induced liver injury in rats.
    Tonomura Y; Kato Y; Hanafusa H; Morikawa Y; Matsuyama K; Uehara T; Ueno M; Torii M
    J Appl Toxicol; 2015 Feb; 35(2):165-72. PubMed ID: 25186495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hy's law: predicting serious hepatotoxicity.
    Temple R
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):241-3. PubMed ID: 16552790
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-Induced Liver Injury Is a Major Risk for New Drugs.
    Seeff LB
    Dig Dis; 2015; 33(4):458-63. PubMed ID: 26159259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Kullak-Ublick GA; Andrade RJ; Merz M; End P; Benesic A; Gerbes AL; Aithal GP
    Gut; 2017 Jun; 66(6):1154-1164. PubMed ID: 28341748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
    Lewis JH
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):221-9. PubMed ID: 16444771
    [No Abstract]   [Full Text] [Related]  

  • 11. How can 'Hy's law' help the clinician?
    Senior JR
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792
    [No Abstract]   [Full Text] [Related]  

  • 12. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval.
    Regev A
    Clin Liver Dis; 2013 Nov; 17(4):749-67, xi. PubMed ID: 24099029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?
    Vuppalanchi R; Liangpunsakul S; Chalasani N
    Am J Gastroenterol; 2007 Mar; 102(3):558-62; quiz 693. PubMed ID: 17156142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study.
    Douros A; Bronder E; Andersohn F; Klimpel A; Thomae M; Sarganas G; Kreutz R; Garbe E
    Br J Clin Pharmacol; 2015 Jun; 79(6):988-99. PubMed ID: 25444550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.
    Shen X; Yuan Z; Mei J; Zhang Z; Guo J; Wu Z; Wu J; Zhang H; Pan J; Huang W; Gong H; Yuan D; Xiao P; Wang Y; Shuai Y; Lin S; Pan Q; Zhou T; Watkins PB; Wu F
    Drug Saf; 2014 Jan; 37(1):43-51. PubMed ID: 24203912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system.
    Ulcickas Yood M; Bortolini M; Casso D; Beck JG; Oliveria SA; Wells KE; Woodcroft KJ; Wang LI
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):427-34. PubMed ID: 25683797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.
    Lo Re V; Haynes K; Forde KA; Goldberg DS; Lewis JD; Carbonari DM; Leidl KB; Reddy KR; Nezamzadeh MS; Roy J; Sha D; Marks AR; De Boer J; Schneider JL; Strom BL; Corley DA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2360-8. PubMed ID: 26122767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transformation in biomarker detection and management of drug-induced liver injury.
    Church RJ; Watkins PB
    Liver Int; 2017 Nov; 37(11):1582-1590. PubMed ID: 28386997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.